336 related articles for article (PubMed ID: 10877734)
1. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.
Swan SK; Rudy DW; Lasseter KC; Ryan CF; Buechel KL; Lambrecht LJ; Pinto MB; Dilzer SC; Obrda O; Sundblad KJ; Gumbs CP; Ebel DL; Quan H; Larson PJ; Schwartz JI; Musliner TA; Gertz BJ; Brater DC; Yao SL
Ann Intern Med; 2000 Jul; 133(1):1-9. PubMed ID: 10877734
[TBL] [Abstract][Full Text] [Related]
2. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin.
Sigthorsson G; Crane R; Simon T; Hoover M; Quan H; Bolognese J; Bjarnason I
Gut; 2000 Oct; 47(4):527-32. PubMed ID: 10986213
[TBL] [Abstract][Full Text] [Related]
3. Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake.
Huledal G; Jonzon B; Malmenäs M; Hedman A; Andersson LI; Odlind B; Brater DC
Clin Pharmacol Ther; 2005 May; 77(5):437-50. PubMed ID: 15900289
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
Yao M; Kargman S; Lam EC; Kelly CR; Zheng Y; Luk P; Kwong E; Evans JF; Wolfe MM
Cancer Res; 2003 Feb; 63(3):586-92. PubMed ID: 12566300
[TBL] [Abstract][Full Text] [Related]
5. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.
Catella-Lawson F; McAdam B; Morrison BW; Kapoor S; Kujubu D; Antes L; Lasseter KC; Quan H; Gertz BJ; FitzGerald GA
J Pharmacol Exp Ther; 1999 May; 289(2):735-41. PubMed ID: 10215647
[TBL] [Abstract][Full Text] [Related]
6. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
Schwartz JI; Vandormael K; Malice MP; Kalyani RN; Lasseter KC; Holmes GB; Gertz BJ; Gottesdiener KM; Laurenzi M; Redfern KJ; Brune K
Clin Pharmacol Ther; 2002 Jul; 72(1):50-61. PubMed ID: 12152004
[TBL] [Abstract][Full Text] [Related]
7. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.
Ehrich EW; Dallob A; De Lepeleire I; Van Hecken A; Riendeau D; Yuan W; Porras A; Wittreich J; Seibold JR; De Schepper P; Mehlisch DR; Gertz BJ
Clin Pharmacol Ther; 1999 Mar; 65(3):336-47. PubMed ID: 10096266
[TBL] [Abstract][Full Text] [Related]
8. Effect of a selective nonsteroidal anti-inflammatory inhibitor of cyclooxygenase-2 on the small bowel of rats.
Leite AZ; Sipahi AM; Damião AO; Garcez AT; Buchpiguel CA; Lopasso FP; Lordello ML; Agostinho CL; Laudanna AA
Braz J Med Biol Res; 2004 Mar; 37(3):333-6. PubMed ID: 15060699
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of COX-2 by inhibition of COX-1 in the rat: a key to NSAID-induced gastric injury.
Tanaka A; Araki H; Hase S; Komoike Y; Takeuchi K
Aliment Pharmacol Ther; 2002 Apr; 16 Suppl 2():90-101. PubMed ID: 11966529
[TBL] [Abstract][Full Text] [Related]
10. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
Bogaty P; Brophy JM; Noel M; Boyer L; Simard S; Bertrand F; Dagenais GR
Circulation; 2004 Aug; 110(8):934-9. PubMed ID: 15302800
[TBL] [Abstract][Full Text] [Related]
11. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.
Laine L; Maller ES; Yu C; Quan H; Simon T
Gastroenterology; 2004 Aug; 127(2):395-402. PubMed ID: 15300570
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
Arch Intern Med; 2000 Oct; 160(19):2998-3003. PubMed ID: 11041909
[TBL] [Abstract][Full Text] [Related]
13. Renal effects of COX-2-selective inhibitors.
Brater DC; Harris C; Redfern JS; Gertz BJ
Am J Nephrol; 2001; 21(1):1-15. PubMed ID: 11275626
[TBL] [Abstract][Full Text] [Related]
14. Safety of a specific COX-2 inhibitor in aspirin-induced asthma.
Szczeklik A; Nizankowska E; Bochenek G; Nagraba K; Mejza F; Swierczynska M
Clin Exp Allergy; 2001 Feb; 31(2):219-25. PubMed ID: 11251623
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects.
Hunt RH; Bowen B; Mortensen ER; Simon TJ; James C; Cagliola A; Quan H; Bolognese JA
Am J Med; 2000 Aug; 109(3):201-6. PubMed ID: 10974182
[TBL] [Abstract][Full Text] [Related]
16. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
[TBL] [Abstract][Full Text] [Related]
17. Effect of rofecoxib on the glomerular filtration rate, proteinuria and the renin-angiotensin-aldosterone system in elderly subjects with chronic renal impairment.
Horackova M; Schück O; Komers R; Charvat J; Teplan V; Kvapil M
Int J Clin Pharmacol Ther; 2005 Sep; 43(9):413-9. PubMed ID: 16163893
[TBL] [Abstract][Full Text] [Related]
18. Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production.
Wight NJ; Gottesdiener K; Garlick NM; Atherton CT; Novak S; Gertz BJ; Calder NA; Cote J; Wong P; Dallob A; Hawkey CJ
Gastroenterology; 2001 Mar; 120(4):867-73. PubMed ID: 11231941
[TBL] [Abstract][Full Text] [Related]
19. The optimal analgesic dose of rofecoxib: Overview of six randomized controlled trials.
Morrison BW; Fricke J; Brown J; Yuan W; Kotey P; Mehlisch D
J Am Dent Assoc; 2000 Dec; 131(12):1729-37. PubMed ID: 11143737
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage.
Tanaka A; Hase S; Miyazawa T; Takeuchi K
J Pharmacol Exp Ther; 2002 Mar; 300(3):754-61. PubMed ID: 11861778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
